NLTX vs. ORGO, FLXN, XBIT, SIGA, RLMD, SYRE, KNSA, ANIP, AKRO, and MNKD
Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Organogenesis (ORGO), Flexion Therapeutics (FLXN), XBiotech (XBIT), SIGA Technologies (SIGA), Relmada Therapeutics (RLMD), Spyre Therapeutics (SYRE), Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), and MannKind (MNKD). These companies are all part of the "medical" sector.
Organogenesis (NASDAQ:ORGO) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
Organogenesis presently has a consensus target price of $4.83, suggesting a potential upside of 80.35%. Given Neoleukin Therapeutics' higher possible upside, equities analysts clearly believe Organogenesis is more favorable than Neoleukin Therapeutics.
Organogenesis has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
Organogenesis received 46 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 66.21% of users gave Organogenesis an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
In the previous week, Organogenesis had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Organogenesis and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.98 beat Organogenesis' score of 0.00 indicating that Organogenesis is being referred to more favorably in the media.
49.6% of Organogenesis shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 34.0% of Organogenesis shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Organogenesis has a net margin of 1.34% compared to Organogenesis' net margin of 0.00%. Neoleukin Therapeutics' return on equity of 2.11% beat Organogenesis' return on equity.
Organogenesis has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Summary
Organogenesis beats Neoleukin Therapeutics on 15 of the 16 factors compared between the two stocks.
Get Neoleukin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neoleukin Therapeutics Competitors List
Related Companies and Tools
